Prostate Carcinoma

The document discussed the effects of 5α-reductase inhibitors, finasteride and dutasteride, on prostate cancer, noting that while they reduced the overall risk of developing prostate cancer, they did not reduce the incidence of high-grade cancers and might have even increased it. The S3 guideline on prostate cancer reflected these findings. New data suggested that prostate cancer-specific mortality could be more effectively reduced through longer-term screening, as opposed to initial findings from the ERSPC study. Active surveillance was gaining importance in early prostate cancer therapy, and new studies showed positive outcomes for patients undergoing surgery for high-risk prostate cancer. Additionally, new immunotherapeutic, chemotherapeutic, and hormonal treatments for metastatic prostate cancer were available or nearing approval.